Sign in
Download Opera News App

Disease-prevention-and-treatment

Patient-First Model: High Tech Meets High Touch for Patients with Rare Disorders

Patient-First Model: High Tech Meets High Touch for Patients with Rare Disorders

Donovan Quill, President and CEO, Optime Care Donovan Quill, President and CEO, Optime Care Industry experts state that orphan drugs will be a major trend to watch in the years ahead, accounting for almost 40% of the Food and Drug Administration approvals this year. This market has become more competitive in the past few years, increasing the potential for reduced costs...

Read Full Story
Donovan Quill Food and Drug Administration